Publication: Glioblastoma multiforme in an Asian population: Evidence for a distinct genetic pathway
Issued Date
2002-11-01
Resource Type
ISSN
0167594X
Other identifier(s)
2-s2.0-0036843770
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Neuro-Oncology. Vol.60, No.2 (2002), 117-125
Suggested Citation
A. Das, W. L. Tan, J. Teo, D. R. Smith Glioblastoma multiforme in an Asian population: Evidence for a distinct genetic pathway. Journal of Neuro-Oncology. Vol.60, No.2 (2002), 117-125. doi:10.1023/A:1020622415786 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/20031
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Glioblastoma multiforme in an Asian population: Evidence for a distinct genetic pathway
Author(s)
Other Contributor(s)
Abstract
In Singapore astrocytic tumours occur in only 25% of patients with primary brain tumours compared to 40-60% in other series. Glioblastoma multiforme arises either de novo as a primary glioblastomas associated with epidermal growth factor receptor (EGFR) and mdm2 over-expression or as a secondary glioblastomas, through malignant progression from low-grade astrocytomas, associated with p53 mutations and PDGFR-α over-expression. Using immunohistochemical methods and DNA sequencing, we studied our population of glioblastomas for over-expression of EGFR, mdm2, p53, and PDGFR-α as well directly for mutations of the p53 gene. While levels of over-expression of EGFR and mdm2 were consistent with levels expected for primary glioblastomas, levels of p53 and PDGFR-α were consistent with levels documented for secondary glioblastomas. Notably 96% of the samples over-expressed p53 as detected with monoclonal antibody pAb 240. Of the 39 samples available for DNA sequencing 18% (7/39) had p53 mutations, including three mutations previously undocumented in glioblastomas. These results provide strong evidence that glioblastomas in Asian patients do not conform to currently accepted models of glioblastoma development, and that clinically defined glioblastomas in these patients show genetic changes consistent with both 'primary' and 'secondary' glioblastomas.